Establishing Interprofessional Clinical Pathways to Prevent Pediatric RSV
Released On
April 15, 2025
Expires On
April 15, 2026
Media Type
Internet
Completion Time
up to 2.75 hours
Specialty
Hospitalist, Infectious Disease, Obstetrics & Gynecology, Pediatrics
Topics
Pediatrics, RSV
This educational activity is presented in collaboration with Rush University Medical Center and Academy for Continued Healthcare Learning (ACHL).
This activity is supported by an educational grant from Sanofi US.
Credit Available
- Physicians - maximum of 2.75 AMA PRA Category 1 Credits™
- Pharmacists - maximum of 2.75 contact hours
- Nurses - 2.75 contact hours
All other healthcare professionals completing this course will be issued a statement of participation.
Target Audience
This educational activity is designed for pediatricians, family practice physicians, NPs and PAs in these settings, neonatologists, hospital pharmacists, and other HCPs who support preventive health practices in children. Other clinicians who may benefit from this education include obstetricians and midwives.
Program Overview
According to the CDC, up to 3% of children in their first year of life are hospitalized due to respiratory syncytial virus (RSV) each year, making it the leading cause of hospitalization among infants in the US. In addition, although prematurity and certain health problems increase the risk for severe RSV, most children hospitalized for RSV in the US have no underlying health conditions or history of preterm birth.
To prevent severe RSV disease in infants, available guidance recommends immunization with nirsevimab for all infants aged <8 months born during or entering their first RSV season (generally October through March), ideally during the birth hospitalization. However, with the availability of this novel preventive approach as well as the availability of a maternal RSV vaccine, many clinicians may have questions surrounding optimal RSV prevention strategies.
To support translation and implementation of the latest recommendations into routine clinical practice, this training program, modeled on the CDC Training of Trainers approach, provides learners with the tools and resources to facilitate peer-to-peer learning with their interprofessional clinical teams.
Learning Objectives
As a result of participating in this educational activity, clinicians should be able to:
- Review RSV prevalence and associated lower respiratory tract infections and hospitalizations in infants
- Evaluate the safety and efficacy data of novel long-acting monoclonal antibody therapies for the prevention of pediatric RSV
- Implement strategies to improve passive immunization rates and mitigate the impact of RSV disease
Faculty
Joseph Domachowske, MD, FAAP, FPIDS
Professor of Pediatrics
Professor of Microbiology and Immunology
Department of Pediatrics
SUNY Upstate Medical University
Syracuse, NY
Kaitlyn Rivard, PharmD
Clinical Pharmacist, Infectious Diseases, Vaccines, and Public Health
Cleveland Clinic
Cleveland, OH
Susan Nelson MSN, RN, CPN (Nurse Planner/Peer Reviewer)
Education Quality Coordinator
Chair RUSH Nursing Documentation Committee
RUSH Department of Professional Nursing Practice
Chicago, IL
Accreditation Statement
In support of improving patient care, Rush University Medical Center is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
This activity is being presented without bias and with commercial support.
Credit Designation
Rush University Medical Center designates this Enduring Material for a maximum of 2.75 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Successful completion of this CME activity, which includes participation in the evaluation component, enables the learner to earn credit toward the CME of the American Board of Surgery’s Continuous Certification program. It is the CME activity provider’s responsibility to submit learner completion information to ACCME for the purpose of granting ABS credit.
Rush University Medical Center designates this Enduring Material for a maximum of 2.75 nursing contact hour(s).
Continuing Pharmacy Education Statement
Rush University Medical Center designates this application-based Internet Enduring Material for a maximum of 2.75 contact hour(s) for pharmacists.
ACPE Universal Activity Number: JA0000275-0000-25-081-H06-P
Disclosures of Conflicts Of Interest
It is the policy of the Interprofessional Continuing Education office at RUSH to ensure that its CE activities are independent, free of commercial bias. Therefore, we manage all financial relationships associated with accredited continuing education activities. RUSH asks everyone who has the ability to control or influence the content of an educational activity to disclose information about all of their financial relationships with ineligible companies within the prior 24 months. An ineligible company is an entity whose primary business is producing, marketing, selling, re-selling or distributing healthcare products used by or on patients. There is no minimum threshold; individuals must disclose all financial relationships, regardless of the amount, with ineligible companies. Individuals must disclose regardless of their view of the relevance of relationships to education. Mechanisms are in place to identify and mitigate any potential conflicts of interest prior to the planning, implementation, or evaluation of the continuing education activity. If a financial relationship is identified for the person in control of content, conflict mitigation strategies will be used to mitigate the financial relationship before they assume their role.
The following financial relationships have been provided:
Joseph Domachowske, MD, FAAP, FPIDS
Consultant: Shionogi, Inc.
Grants/Research: Glaxo Smith Kline, Moderna, Pfizer, Sanofi, Shionogi, Inc.
Independent Contractor: Glaxo Smith Kline, Moderna, Sanofi, Shionogi, Inc.
Kaitlyn Rivard, PharmD
Advisor: Pfizer
Consultant: Wolters Kluwer
Susan Nelson MSN, RN, CPN
No financial relationships to disclose
Staff and Reviewer Disclosures
Rush University Medical Center and the Office of Interprofessional Continuing Education staff members, ACHL staff members, and others involved with the planning, development, and review of the content for this activity have no relevant affiliations or financial relationships to disclose.
Method of Participation
This activity will take up to 2.75 hours to complete. To receive credit, learners are required to complete the pretest, view the online activity, and complete the posttest and evaluation. To receive credit, 80% must be achieved on the posttest. A certificate will be immediately available. There is no fee to participate in the activity or for the generation of the certificate.
For questions, contact Laurie Novoryta at [email protected].
The CPE credits will be posted in the NABP profile within 30 days of participation.
Course Viewing Requirements
Internet Explorer 8.0+ for Windows 2003, Vista, XP, Windows 7, Windows 8.1 and above
Google Chrome 28.0+ for Windows, Mac OS, or Linux
Mozilla Firefox 23.0+ for Windows, Mac OS, or Linux
Safari 6.0+ for Mac OSX 10.7 and above
Supported Phones & Tablets
Android 4.0.3 and above
iPhone/iPad with iOS 6.1 or above
Disclaimer
The content for this activity was developed independently of any ineligible company. All materials are included with permission. The opinions expressed are those of the faculty and are not to be construed as those of the publisher or grantor(s).
This educational activity was planned and produced in accordance with the ACCME Standards for Integrity and Independence in Accredited Continuing Education. Recommendations involving clinical medicine in a continuing medical education (CME/CE) activity must be based on evidence that is accepted within the profession of medicine as adequate justification for their indications and contraindications in the care of patients. All scientific research referred to, reported, or used in CME/CE in support or justification of a patient care recommendation must conform to the generally accepted standards of experimental design, data collection, and analysis.
Unapproved Uses of Drugs/Devices: In accordance with requirements of the FDA, the audience is advised that information presented in this continuing medical education activity may contain references to unlabeled or unapproved uses of drugs or devices. Please refer to the FDA approved package insert for each drug/device for full prescribing/utilization information.